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Abstract
Background: Yes-associated protein (YAP), an essential component of Hippo pathway, was identified as an
oncoprotein which participated in the progression of various malignancies. However, its role in chronic myeloid
leukemia (CML) remains to be further clarified.
Methods: The expression of YAP in CML cells was determined by western blotting. Next, the effects of YAP
knockdown and YAP inhibitor on CML cells were evaluated by MTT assay, flow cytometry (FCM) and Wright’s
staining. Moreover, K562 induced mice model was employed to further investigate the role of YAP in vivo.
Results: YAP was overexpressed in CML cells. Knockdown of YAP by si-RNA or inhibition the function of YAP using
verteporfin (VP) not only inhibited the proliferation, induced the apoptosis of CML cells but also reduced the
expression of YAP target genes c-myc and survivin. Additionally, VP enhanced the efficacy of imatinib (IM) in vitro
and suppressed leukemogenesis in vivo.
Conclusion: Our results indicate that YAP may play an important role in the proliferation and leukemogenesis of
CML cells. Genetic or pharmacological inhibition of YAP provides a novel treatment strategy for CML.
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PI, Propidium iodide; TKIs, Tyrosine kinase inhibitors; VP, Verteporfin; YAP, Yes-associated protein
Background
Chronic myeloid leukemia (CML) is a clonal disorder
characterized by BCR/ABL, a constitutively activated
tyrosine kinase generated from the reciprocal transloca-
tion between chromosomes 9 and 22 [1–5]. BCR/ABL
activates multiple pathways involved in the regulation of
cell proliferation and apoptosis such as PI3K-AKT [6],
MEK-ERK [7, 8] and STAT5 [9], resulting in progressive
granulocytosis. Patients newly diagnosed with CML are
commonly treated with inhibitor of BCR/ABL named
imatinib (IM) [10]. However, tyrosine kinase inhibitors
(TKIs)-resistance due to the occurrence of mutations
and the limited action of TKIs in patients with blast crisis
have emerged as significant clinical issues [11]. Therefore,
it is urgent to find more efficient therapeutic strategies to
overcome these problems.
Hippo pathway, firstly discovered in Drosophila, is evo-
lutionarily conserved in mammals. This pathway plays
an important role in controlling organ size, regulating
self-renewal and differentiation of stem cells [12–14].
In vertebrates, the Hippo pathway functions through a
kinase cascade comprises of two kinases Mst and Lats,
and their co-factors WW45 and Mob. Normally, when cells
proliferate to a high density, Hippo pathway is activated
[15]. First, Mst1/2 forms a complex with Sav1, and then the
complex phosphorylates Lats1/2. Activated Lats1/2 further
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phosphorylates YAP on Ser127 and promotes its cytoplas-
mic retention and subsequent degradation by ubiquitin-
proteasome pathway [16, 17].
Unfortunately, Hippo pathway has been found to be
inactive in various kinds of malignant tumors [18–20].
In these tumor cells, YAP can not be phosphorylated
and degraded effectively. Unphosphorylated YAP enters
into the nucleus where YAP binds and activates transcrip-
tion factors, altering the expression of genes involved in
cell proliferation and apoptosis [21–23]. In addition, YAP
has been identified as an oncoprotein elevated in cholan-
giocarcinoma [24], ovarian cancer [25], colorectal cancer
[26], hepatocellular carcinoma [27] and gastric cancer
[28]. YAP has also been found to act as a stem cell
regulator [29, 30] and is highly expressed in the stem
cell fractions [31]. Moreover, it has been revealed that
the expression of YAP was significantly higher in CLL
(chronic lymphoblastic leukemia) patients than that in
health donors [32]. Although it has been demonstrated
that YAP – induced apoptosis was mediated by the ab-
errant presence of ABL1 in the nucleus in MM cells
[33], in CML cells where ABL1 was commonly translo-
cated, the function of YAP was unclear. Considering
that c-Myc and survivin, target genes of both BCR/ABL
and Hippo-YAP pathways which are associated with the
regulation of cell proliferation, are involved in the progres-
sion and response to IM in CML [34–37], the role of YAP
in the pathogenesis of CML may be interesting to explore.
In this study we found that YAP was highly expressed
in bone marrow mononuclear cells (BMMNCs) from
CML patients and CML cell lines. We also found knock-
down of YAP inhibited the proliferation and induced
apoptosis of CML cells. Importantly, we demonstrated
that inhibition of YAP by veterporfin (VP) significantly
increased the efficacy of IM in vitro and in vivo. Taken
together, this is the first report which examined the role
of YAP in CML and the effect of YAP inhibition on the
response of CML cells to IM. It may provide a feasible
therapeutic strategy in the treatment of CML.
Methods
Cell culture
The 32DP and BP210 cell lines were generated from
32D and BaF3 cell lines respectively by stably transformed by
p210BCR-ABL. K562, K562/G01, 32DP, BP210, HL-60, THP1
and NB4 cells were maintained in RPMI-1640 (Gibco, USA)
supplemented with 10 % fetal bovine serum (Gibco, USA).
For 32D and Ba/F3 cells, 1 ng/ml of murine IL-3
(PeproTech, USA) was added to the medium. All cells were
cultured at 37 °C in a humidified atmosphere with 5 % CO2.
Clinical samples
Bone marrow (BM) of normal individuals (5 cases) and
CML patients (9 cases) were obtained from the first
affiliated hospital of Chongqing Medical University,
Chongqing, China. Mononuclear cells were isolated using
human bone marrow mononuclear cells isolation kit
(Tbd science, Tianjin, China).
Small molecules, siRNA, and antibodies
The siRNA targeting YAP and the non-targeting siRNA
were purchased from Ruibobio (Guangzhou, China). The
target sequences for YAP siRNA are 5′-GCGUAGCCA
GUUACCAACA dTdT-3′, 5′- CAGUGGCACCUAUCA
CUCU dTdT-3′ and 5′- GGUGAUACUAUCAACCAAA
dTdT-3′. IM was obtained from Novartis (Basel,
Switzerland) and VP from Selleckchem (Houston, TX).
Following antibodies were used in this study: anti-
YAP(S127), anti-YAP(S397), anti-Bax, anti-caspase-3,
anti-PARP, anti-p21 (Cell Signaling Technology, USA);
anti-YAP and the HRP-conjugated secondary antibodies
(Santa Cruz Biotechnology, USA); anti-CyclinD1, anti-
survivin and anti-c-Myc (Bioworld Technology Inc, USA);
anti-β-Actin (Zhong shan jin qiao, China).
Small molecule treatment and RNA interference
2 × 105 cells were plated in 6-well plates and trans-
fected with 50 pmol of siRNA using Lipofectamine
2000 (Invitrogen, NY, USA) according to the manufac-
turer’s protocol. After transfection for 48 h, cells were
harvested for viability, cell cycle and apoptosis analysis.
Small molecule inhibitors IM and VP were dissolved in
DMSO. Cells treated with these inhibitors were col-
lected at indicated time for further analysis.
Western blotting
Cells were collected and lysed by RAPI lysis buffer sup-
plemented with proteinase and phosphatase inhibitors
(Cell Signal, USA) at 4 °C for 20 min. After centrifuged
at 4 °C for 15 min at 13,000 g the supernatants were col-
lected. Then equal amounts of extracts (60 μg) were sep-
arated by 8–10 % SDS-PAGE and transferred onto the
PVDF membranes (Millipore, Boston, MA, USA), and
was blocked in 5 % nonfat milk/TBST, incubated with
indicated antibodies overnight at 4 °C, followed by incu-
bation with HRP-conjugated secondary antibody for 1 h
at 37 °C. Detection was performed using the enhanced
chemiluminescence substrate (ECL) (Millipore, USA).
Signals were visualized and analyzed by the Bio-Rad Gel
Imaging System on cool image workstation II (Viagene,
USA).
Apoptotic and cell cycle analysis
Cells were collected after been treated with DMSO, VP
(10 μM) or VP combined with IM (2 μM) respectively
for 48 h. Apoptosis was assessed by flow cytometry (FCM)
using an Apoptosis Detection Kit (Becton-Dickinson) ac-
cording to the manufacturer’s instruction. Moreover, cell
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morphology was examined by Wright’s staining and the
results were observed with light microscope.
The cell cycle was analyzed by propidium iodide (PI)
staining and quantified using FCM. The percentage of
cells in different phases of the cell cycle was determined
and quantitated by software (Becton, Dickinson, San
Jose, CA, USA).
MTT assay
For MTT assay, 2× 103 of treated cells were seeded in
per well of 96-well plates, then 50 μL MTT (2 mg/ml in
PBS) (Sigma, USA) was added at indicated time, and in-
cubated for 4 h at 37 °C. Then plates were centrifuged at
2000 rpm for 10 min. Supernatant was removed carefully.
150 μL of DMSO was added to each well. After shaking
for 10 min the absorbance at 492 nm was measured by
micro-plate reader (Eon, BioTeck, USA).
Murine leukemogenesis model
2.0 × 107 K562 cells were injected intravenously into
NOD/SCID mice of 5–6 weeks old (n = 5, each group).
From the second week, VP (50 mg/kg/mouse) was ap-
plied by intra-peritoneal (IP) and IM (100 mg/kg/mouse)
was given by gavage. VP, IM and their combination were
delivered every other day for four weeks while PBS was
used as control. State, weight change and white blood
cell counts of the mice were monitored weekly during
administration of drugs. Furthermore, to detect the pro-
portion of human-CD45 positive cells, peripheral blood
cells were collected and white blood cells were separated
from each group. The proportion of human-CD45 posi-
tive cells was detected by FCM.
Statistical methods
Each experiment in this study was repeated for three
times and values were summarized and represented as
means ± standard deviations. The statistical analyses
were performed by one-way ANOVA analysis to compare
the mean of each group with that of the control group. All
statistical analyses were performed using SPSS software.
p-values < 0.05 was considered statistically significant.
Results
YAP is up-regulated in samples from CML patients and CML
cell lines
To determine the potential role of YAP in CML, we de-
tected the expression of YAP in BMMNCs from healthy
individuals (n = 5) and CML patients (n = 9) in different
phases. Western blotting showed YAP was up-regulated
in CML patients compared with the normal controls
(Fig. 1a). RT-PCR showed no significant difference be-
tween each group (Fig. 1b). Next, we determined the ex-
pression of YAP in BCR/ABL+ leukemia cell lines (K562,
KCL22 and K562/G01) and BCR/ABL− cell lines (HL60,
NB4 and THP1). Western blotting showed the protein
level of YAP was much higher in BCR/ABL+ leukemia
cell lines than that in BCR/ABL− ones (Fig. 1c).
Previous studies have showed that c-Abl kinase activity
can be activated in response to DNA damage [38]. Under
this condition, activated c-Abl phosphorylates and stabi-
lizes YAP in a kinase-dependent manner [39]. In CML,
BCR-ABL is constitutively active. To confirm whether the
up-regulation of YAP detected in BCR/ABL+ cells is asso-
ciated with the tyrosine kinase activity of BCR/ABL, we
compared the level of YAP in 32D, BaF3 and BCR/ABL
transformed 32DP and BP210 cells. Furthermore, IM
(2 μM) was used to inhibit the activity of BCR/ABL. The
results indicated that the ectopic expression of BCR/ABL
up-regulated protein level of YAP (Fig. 1d) but not mRNA
level (Fig. 1e) and inhibition of BCR/ABL by IM reduced
the expression of YAP at protein level (Fig. 1f) but not at
transcription level (Fig. 1g). Here we found the expression
of p-YAP(S127) increased first and then decreased after
treated by IM (Additional file 1: Figure S1D). Overall, the
results suggest that YAP might be involved in CML.
Silencing of YAP inhibits the proliferation of CML cells
YAP-targeted therapy has obtained positive effects in
various malignant cells [40]. Here we assessed the
therapeutic potential of YAP in CML cell lines K562
and IM-resistant K562/G01. siRNA was used to knock-
down YAP. The knockdown efficiency was examined by
RT-PCR and western blotting (Fig. 2a). ctgf and cyr61
were detected to confirm the knockdown efficiency of
siRNA (Additional file 1: Figure S1A, B). MTT showed
that silencing of YAP significantly suppressed the prolifer-
ation of CML cells (Fig. 2b). FCM analysis demonstrated
that knockdown of YAP induced blockade of cell cycle
progression from G1 to S phase (Fig. 2c). Moreover, the
expression of Cyclin D1 was decreased and the expression
of p21 was increased in YAP silenced K562 and K562/
G01cells (Fig. 2d).
Silencing of YAP induces apoptosis of CML cells
Results of FCM showed that knockdown of YAP promotes
apoptosis in CML cells (Fig. 3a). YAP silenced K562
and K562/G01 cells exhibited apoptosis characteristic
morphological changes (Fig. 3b). Western blot analysis
showed that the expression of proteins associated with
apoptosis such as Bax, Caspase-3 and PARP cleavage prod-
ucts were increased in YAP silenced CML cells (Fig. 3c).
RT-PCR and western blotting analysis were conducted to
verify whether the expression of c-Myc and survivin, co-
target genes of BCR-ABL and Hippo/YAP pathway, were
changed by YAP silencing. The results illustrated that
knockdown of YAP down-regulated c-Myc and survivin
both at protein (Fig. 3d) and mRNA levels (Fig. 3e). These
results indicated that after inducing cell cycle arrest,
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silencing of YAP triggered apoptosis of CML cells via regu-
lating the expression of apoptosis-related proteins.
YAP inhibitor enhances the effect of IM on CML cells
VP is a kind of inhibitor which can block the association
of TEAD and YAP. Disruption of the TEAD-YAP com-
plex suppresses the transcription of downstream genes
[41]. It has been demonstrated that VP can sensitize
cells to cytotoxics [42, 43]. To investigate the function of
VP in CML cells, the concentration of VP used in our
study was determined. K562 and K562/G01 were treated
with VP at a series of concentrations (0.0 μM, 0.5 μM,
1 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM) for 48 h.
The 50 % inhibitive concentration (IC50) was detected
by MTT assay. The result showed that the IC50 value of
K562 and K562/G01 was 10.281 ± 1.485 μM and 11.433 ±
1.675 μM, respectively (Fig. 4a). To explore whether the
inhibition of YAP by VP can enhance the effect of IM on
K562 and K562/G01, cells were treated with IM (2 μM),
VP (10 μM) and IM combined with VP respectively.
Compared with DMSO group, cells in IM and VP groups
showed a decreased proliferation rate. The combination
of VP and IM dramatically inhibited cell proliferation
(Fig. 4b). Cell cycle analysis showed that VP promoted
Fig. 1 Expressions of YAP in BMMNCs from CML patients and different leukemic cell lines. a The protein expression of YAP was up-regulated in
BMMNCs separated from CML patients in different phases (n = 9) compared with that from the healthy individuals (n = 5). b the mRNA level of YAP
showed no significant difference between CML patients and the healthy individuals. c YAP was up-regulated in BCR/ABL positive cell lines K562, KCL22
and K562G01compared with BCR/ABL negative cell lines HL60, NB4 and THP. d The ectopic expression of BCR/ABL dramatically up-regulated
YAP at protein level (**P < 0.01) but not mRNA level (e). Inhibition of BCR/ABL by IM down-regulated YAP at protein level (f) (**P < 0.01) but
not mRNA level (g)
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Fig. 2 Silencing of YAP inhibits the proliferation of CML cells. a Knockdown efficiency of siRNA was validated by western blotting analysis. b Cell
viability was determined by MTT, viability of siRNA transfected K562 and K562/G01 decreased in a time dependent manner (**p < 0.01). c Cell cycle
was analyzed by flow cytometry at 48 h after transfection. d The expression of P21 and Cyclin D1 were analyzed by western blot
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Fig. 3 Silencing of YAP induces apoptosis of CML cells. a The percentage of apoptotic cells were examined by FCM. b Morphological features of
the cell apoptosis induced by si-YAP (50 nM). c The expression of Bax, cleaved caspase-3 and PARP were analyzed by western blot. Knockdown of
YAP by siRNA down-regulated c-Myc and survivin both at protein (d) and mRNA levels (e) (**P < 0.01)
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cell cycle arrest in G0/G1 phase induced by IM (Fig. 4c).
VP remarkably facilitated IM induced apoptosis in
CML cells (Fig. 4d and Additional file 1: Figure S1C).
Meanwhile, to reveal the molecular mechanisms in-
volved in YAP inhibition-mediated cell cycle arrest and
apoptosis promotion, western blotting was conducted
and the expression of associated proteins were detected.
As shown in Fig. 4e, the combination of VP and IM in-
duced down-regulation of c-Myc, survivin, Cyclin D1 and
up-regulation of p21, Bax, Caspase-3 and PARP cleavage
products compared to the treatment with IM or VP alone.
YAP inhibitor potentiates the efficacy of IM on
leukemogenesis in vivo
Whether inhibition of YAP could enhance the effect of
IM on leukemogenesis induced by K562 cells was exam-
ined. First, the same numbers of K562 (2 × 107) were
injected into NOD-SCID mice intravenously. One week
later, mice were treated with PBS, IM, VP and VP com-
bined with IM respectively. The results showed that
mice of PBS group displayed higher white blood cell
counts compared with mice of IM, VP and the combin-
ation groups (Fig. 5a). Liver and spleen were excised and
Fig. 4 YAP inhibitor enhances the effect of IM on CML cells. a K562 and K562/G01 cells were treated with different dose of VP and the inhibitory
rate was increased as a dose-dependent manner. b K562 and K562/G01 cells were treated with VP (10 μM) with or without 2 μM IM for 24 h, and
cell viability was evaluated by MTT assay. c Cell cycle distribution was examined by FCM. d Apoptotic rate was analyzed by FCM. e After K562
and K562/G01cells were treated with VP, IM or their combination for 24 h, the expression of c-Myc, survivin, P21, Cyclin D1, Bax and the Cleaved
caspase-3 and PARP were detected by western blot. *p < 0.05 and **p < 0.01 versus control group, #p < 0.05 versus IM alone
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weighted. As shown in Fig. 5b, c and d, mice in PBS
group have more severe splenomegaly and hepatomegaly
compared with IM and VP groups. The combination of
VP and IM partly alleviates these phenomenons.
Infiltration of leukemic cells in the liver and spleen
was also examined by hematoxylin/eosin (HE) staining.
Mice treated with IM, VP or their combination were ob-
served with a reduced leukemic cell infiltration (Fig. 5e).
Morphology of bone marrow also showed a decreased
Myeloid : Erythroid ratio in mice treated with IM, VP
and both of them (Fig. 5e). Peripheral blood cells were
collected from each group and the proportion of
human-CD45 positive cells which indicates the number
of leukemic cells in murine bone marrow was detected
by FCM. A significant reduction of CD45 positive cells
was observed in the IM + VP group compared with IM
and VP groups (Fig. 5f ). Survival time of mice in com-
bination group was significantly prolonged compared
with the other groups (Fig. 5g). The mRNA expression
level of YAP was detected, but no significant difference
was found (Additional file 1: Figure S1E). The remaining
samples were not enough for performing western blot,
so we did not determin the protein level of YAP. These
results further confirmed that inhibition of YAP by VP
significantly increases the cytotoxicity of IM in vivo.
Discussion
Our study revealed that YAP might be involved in the
pathogenesis of CML and could be a potential target for
the treatment of CML. We showed that YAP had a
Fig. 5 YAP inhibitor potentiates the efficacy of IM on leukemogenesis in vivo. a Total WBC count in PBS, VP, VP and IM group were determined.
b, c Mean liver and spleen weight of mice in different group were quantified. d Representative images of livers and spleens from four groups.
e Histologic sections of liver and spleen were stained with H&E and bone marrow cells from mice in each group were stained with Wright’s
staining. f Percentage of Human CD45+ cells in murine bone marrow were detected by flow cytometry. g Survival curves were analyzed by
Kaplan–Meier methods. *p < 0.05 and **p < 0.01 versus control group, #p < 0.05 and ##p < 0.01 versus IM alone
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elevated level both in CML cell lines and BMMNCs
from CML patients. Pharmacological or genetic inhib-
ition of YAP efficaciously suppressed cell proliferation,
induced cell cycle arrest in G1 phase and promoted
apoptosis in CML cells. Moreover, the results derived
from in vivo leukemogenesis assay also confirmed that
inhibition of YAP enhanced the effects of IM on CML
cells. Results of our study showed that the protein ex-
pression level of YAP was higher in BCR/ABL positive
cell lines compared with BCR/ABL negative ones but
there was no significant difference in the transcription
level of YAP between them. Inhibition of BCR/ABL kinase
activity by IM decreased protein level of YAP.
Previous study has demonstrated the activation of c-
Abl induced by DNA damage antagonizes YAP oncogenic
function via phosphorylating it at the Y357 residue
[39, 44]. Different with c-Abl which is activated by
DNA damage [45] and shuttles between the nucleus
and cytoplasm [46], BCR/ABL mainly localizes in the
cytoplasm and has constitutive activity [47]. As mentioned
above, BCR/ABL activates PI3K-AKT and MEK-ERK
pathways and both of them take part in the regulation
of YAP. Activation of EGFR-PI3K-Akt signaling pathway
up-regulates the expression of YAP, promotes its trans-
location into the nucleus to regulate the transcription
of several downstream genes in diabetic mouse renal
proximal tubule epithelial cells [48]. ERK1/2 inhibition
decreases YAP protein level and down-regulates tran-
scriptional activity of the Hippo pathway in non small
cell lung cancer (NSCLC) cell lines [49]. These results
suggest that BCR/ABL might influence the protein level
of YAP through activating downstream pathways and
influencing its stability, but the exact mechanism needs
to be further investigated.
As a kinase of Hippo pathway, Lats2 has been demon-
strated to prevent apoptosis induced by DNA damage
through inhibition of c-Abl [50]. Although both of c-Abl
and BCR/ABL have SH3 domain which could bind to
Lats2, the function of Lats2 was not clear in CML. Former
research has demonstrated that the expression of Lats2
was downregulated in K562 cells [51], which suggested
that maybe in CML cells low level of Lats2 influenced its
function.
It has been reported that YAP functions as an oncopro-
tein [26, 27, 52–54] by interacting with TEAD [55], forming
a protein complex which is critical for the transcription of
downstream genes such as c-Myc, and survivin [56, 57].
Porphyrin family members like VP, hematoporphyrin (HP)
and protoporphyrin IX (PPIX) have been found as inhibi-
tors of YAP through abrogating the interaction between
YAP and TEAD [41]. Inhibition of YAP by VP synergis-
tically inhibits esophageal cancer (EC) cells growth when
in combination with 5-FU in vitro and in vivo [43]. But in
CML, the function of VP is not clear. Here, we demonstrate
that VP suppresses proliferation of CML cell and enhances
the efficacy of IM in vitro and in vivo.
Overexpression of YAP/TAZ and survivin is commonly
seen in malignancies [58]. Silencing of YAP enhances the
efficacy of survivin inhibitor, indicating that simultaneous
targeting these two molecules may achieve better thera-
peutic effect [59]. In CML, both of c-Myc and survivin are
involved in the progression of CML [35, 60]. c-Myc is up-
regulated by BCR/ABL [36, 61]. IM down-regulates c-Myc
in CML cell lines and higher level of c-Myc at diagnosis
correlates with worse response to IM [37]. Besides, target-
ing survivin sensitizes CML cells to IM and other cyto-
toxic drugs [62, 63]. In this study, we found that both
genetic and pharmacological inhibition of YAP markedly
reduced the expression of c-Myc and survivin. These
results indicate that targeting YAP might influence the
response of CML cells to IM via down-regulating the
expression of c-Myc and survivin.
Conclusions
In summary, our results demonstrated for the first time that
YAP is involved in the pathogenesis of CML. YAP-targeted
therapy may be a promising strategy with a better thera-
peutic effect in the presence of pharmacological inhibitors
of BCR/ABL like IM.
Additional file
Additional file 1: (A), (B) Knockdown of YAP by siRNA down-regulated
ctgf and cyr61 at mRNA levels (**P < 0.01). (C) Morphological changes of
cell apoptosis induced by VP (10 μM, 24 h) with or without IM (2 μM). (D)
IM decreased the protein level of YAP while the expression of p-YAP(S127)
increased first and then decreased. (E) The mRNA level of YAP in bone cells
collected from each group and the results showed no significant difference.
(TIF 1855 kb)
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